Navigation Links
Misonix Announces Participation in Annual Diabetic Foot Global Conference

FARMINGDALE, N.Y., May 12 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced their attendance and participation in the annual Diabetic Foot Global Conference (DFCON), which was held in Los Angeles, CA, March 19-21, 2009. In addition to exhibiting its SonicOne(R) Ultrasonic Wound Cleansing and Debridement System to the approximately 950 clinicians in attendance, Misonix provided an educational grant to support a series of workshops dedicated to improving wound debridement techniques, which was led by Vickie R. Driver, MS, DPM, FACFAS, Director of Clinical Research Foot Care at the Boston Medical Center and Boston University School of Medicine. As part of her lecture, Dr. Driver presented details on the advantages of using ultrasonic debridement as compared to other modalities. Post lecture, over 90 attendees participated in "hands on" demonstrations of the SonicOne.

DFCON is dedicated to educating clinical professionals regarding diseases, circulation deficiencies, and non-healing wounds of the lower extremities and the appropriate treatment protocols. Healing of wounds, revascularization, and prevention of amputation are included in their overall strategy for positive patient outcomes.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is pleased to demonstrate its commitment to the over one billion dollars per year wound care market by supporting important research and treatment programs like DFCON," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The wound care product platform is an essential component of our product portfolio, as demonstrated by our commitment to expanding hospital direct sales in the United States and our network of specialty distributors in export markets."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath
    Cameron Associates, Inc.

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
2. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
3. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
4. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
5. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
6. Misonix Announces New HIFU Distribution Agreement for Italy
7. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
8. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
9. Misonix Announces New Distribution Agreement for Israel
10. Misonix Announces New Sales Agency Agreement for Eastern Europe
11. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
Post Your Comments:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: